PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Envigo launches PATHWAY, an optimized safety assessment solution to enable first-in-human clinical trials

11 March 2019, East Millstone, N.J. – Envigo, a leading provider of non-clinical contract research services and research models, announced today the launch of PATHWAY – an integrated solution that optimizes non-clinical safety assessment programs to enable first-in-human clinical trials. 

PATHWAY is designed to manage the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers by integrating safety assessment study types and bioanalytical support with scientific and regulatory consulting, program design and project management.

The decision to develop the PATHWAY solution was made in order to help our customers navigate the increased scientific and regulatory complexity facing advanced therapies going through safety assessment.  The intricacy of design and management of these critical non-clinical programs, and the level of interaction with regulatory bodies required, raises the risk of introducing delays and costs to development programs.  PATHWAY has been designed to leverage Envigo’s capacity, capabilities and experience in the field to optimize safety assessment programs and deliver translational biology insights to prepare customers for first-in-human clinical trials. 

“Our deep expertise in the complex fields of biologics and advanced therapies adds particular value to our customers with drug development programs in these growing categories. On our customers’ behalf, we frequently work with regulators to determine the most appropriate interpretation of regulatory guidance as it applies to a specific therapeutic,” commented Lee Coney, Envigo’s Chief Scientific Officer.

“PATHWAY makes full use of our beginning-to-end understanding of the safety assessment process, and optimizes the journey to first-in-human studies.  Experience of designing and conducting studies in a wide range of therapeutic modalities, and in working with regulatory agencies around the world, means we are able to anticipate the needs of a program at design stage, plan studies accordingly, and manage an optimal timeline of study execution,” Lee Coney added.

With harmonized facilities with AAALAC accreditation in Europe and North America, Envigo further seeks to optimize safety assessment programs by ensuring studies are carried out at centers of excellence and where capacity permits the earliest possible start date for commencing work. 

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026